Albion Financial Group’s Inovio Pharmaceuticals INO Stock Holding History

Albion Financial Group’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6	Hold	5	–	–	﹤0.01%	647
2026 Q1	$9	Hold	5	–	–	﹤0.01%	733
2025 Q4	$9	Hold	5	–	–	﹤0.01%	648
2025 Q3	$12	Hold	5	–	–	﹤0.01%	649
2025 Q2	$11	Hold	5	–	–	﹤0.01%	583
2025 Q1	$9	Hold	5	–	–	﹤0.01%	605
2024 Q4	$10	Hold	5	–	–	﹤0.01%	679
2024 Q3	$29	Hold	5	–	–	﹤0.01%	504
2024 Q2	$41	Hold	5	–	–	﹤0.01%	505
2024 Q1	$70	Buy	+5	New	+$43	﹤0.01%	494
2023 Q4	–	Sell	-5	Closed	-$25	–	486
2023 Q3	$25	Hold	5	–	–	﹤0.01%	470
2023 Q2	$29	Hold	5	–	–	﹤0.01%	467
2023 Q1	$52	Hold	5	–	–	﹤0.01%	440
2022 Q4	$98	Hold	5	–	–	﹤0.01%	475
2022 Q3	$0	Hold	5	–	–	﹤0.01%	504
2022 Q2	$0	Hold	5	–	–	﹤0.01%	574
2022 Q1	$0	Hold	5	–	–	﹤0.01%	626
2021 Q4	$0	Hold	5	–	–	﹤0.01%	648
2021 Q3	$0	Hold	5	–	–	﹤0.01%	532
2021 Q2	$1K	Buy	+5	New	+$480	﹤0.01%	485
2020 Q4	$1K	Buy	+5	New	+$666	﹤0.01%	452

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Albion Financial Group's INO Position: Q2 2026 in Review

Albion Financial Group held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 5 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #647.

Albion Financial Group first reported a position in INO in Q4 2020 and has held it in 21 quarters since. The position peaked at $1K in Q2 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Albion Financial Group held 5 shares of Inovio Pharmaceuticals worth $6 as of Q2 2026.
Albion Financial Group left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Albion Financial Group's portfolio in Q2 2026, its #647 holding.
Albion Financial Group first reported a position in Inovio Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
Albion Financial Group's Inovio Pharmaceuticals position peaked at $1K in Q2 2021.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.